Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days

Respiratory Medicine Case Reports

Volumn 22, Issue , 2017, Pages 31-33

  Iijima, Yuki ^a   Hirotsu, Yosuke ^a   Amemiya, Kenji ^a   Higashi, Seishi ^b   Miyashita, Yoshihiro ^a   Omata, Masao ^c  

^a Yamanashi Prefectural Central Hospital   (Japan)

^b Shiokawa Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Circulating tumor DNA; Immune checkpoint therapy; Lung cancer; Nivolumab; PD 1

Indexed keywords

AFATINIB; CARBOPLATIN; CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NIVOLUMAB; PEMETREXED; PROTEIN P53; STAGE SPECIFIC EMBRYO ANTIGEN 1;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CAUSE OF DEATH; DRUG EFFICACY; DRUG SAFETY; EGFR GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LOW BACK PAIN; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; NEEDLE BIOPSY; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; TP53 GENE; TREATMENT FAILURE; TUMOR VOLUME;

EID: 85020272953     PISSN: None     EISSN: 22130071     Source Type: Journal    
DOI: 10.1016/j.rmcr.2017.05.015     Document Type: Article

References (17)

1. Brahmer, J.R., Drake, C.G., Wollner, I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28 (2010), 3167–3175.
2. Wang, C., Thudium, K.B., Han, M., et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2 (2014), 846–856.
3. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
4. Lipson, E.J., Sharfman, W.H., Drake, C.G., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19 (2013), 462–468.
5. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
6. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
7. Topalian, S.L., Sznol, M., McDermott, D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
8. Ribas, A., Chmielowski, B., Glaspy, J.A., Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin. Cancer Res. 15 (2009), 7116–7118.
9. Heitzer, E., Ulz, P., Geigl, J.B., Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61 (2015), 112–123.
10. Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32 (2014), 579–586.
11. Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
12. Cancer Genome Atlas Research Network, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
13. Goto, T., Hirotsu, Y., Oyama, T., et al. Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients. Med. Oncol., 33, 2016, 29, 10.1007/s12032-016-0744-x.
14. Kato, K., Uchida, J., Kukita, Y., et al. Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. Sci. Rep., 6, 2016, 29093.
15. Diehl, F., Schmidt, K., Choti, M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14 (2008), 985–990.
16. Lipson, E.J., Velculescu, V.E., Pritchard, T.S., et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J. Immunother. Cancer, 2, 2014, 42.
17. Imamura, F., Uchida, J., Kukita, Y., et al. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer 94 (2016), 68–73.